STOCK TITAN

Intercept to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Intercept Pharmaceuticals (Nasdaq:ICPT) announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020, from 3:30 to 3:55 p.m. ET. Key executives, including President and CEO Mark Pruzanski and CFO Sandip Kapadia, will engage in a fireside chat. A live webcast will be accessible on Intercept's investor page, with an audio archive available for two weeks post-event. Intercept focuses on novel therapeutics for progressive non-viral liver diseases, particularly primary biliary cholangitis and nonalcoholic steatohepatitis.

Positive
  • None.
Negative
  • None.

NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Mark Pruzanski, M.D., President and Chief Executive Officer, Sandip Kapadia, Chief Financial Officer, and Gail Cawkwell, M.D., Ph.D., SVP, Medical Affairs, Safety and Pharmacovigilance of Intercept, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Tuesday, December 1, 2020 from 3:30 – 3:55 p.m. ET.

A live webcast of the event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An audio archive of the webcast will also be available on Intercept’s website for approximately two weeks.

About Intercept

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

Contact

For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com 

Media inquiries: media@interceptpharma.com 


FAQ

What event will Intercept Pharmaceuticals participate in on December 1, 2020?

Intercept Pharmaceuticals will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020.

Who are the key executives participating in the conference for Intercept Pharmaceuticals?

Mark Pruzanski, M.D., Sandip Kapadia, and Gail Cawkwell, M.D., Ph.D., will represent Intercept Pharmaceuticals at the conference.

How can I watch the Intercept Pharmaceuticals conference live?

A live webcast of the conference can be viewed on Intercept's investor page.

What is the focus of Intercept Pharmaceuticals?

Intercept Pharmaceuticals focuses on developing therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.

Will there be a recording of the Intercept Pharmaceuticals conference available?

Yes, an audio archive of the webcast will be available on Intercept’s website for about two weeks after the event.

Intercept Pharmaceuticals, Inc.

NASDAQ:ICPT

ICPT Rankings

ICPT Latest News

ICPT Stock Data

794.69M
40.45M
3.13%
81.3%
24.24%
Biotechnology
Healthcare
Link
United States
Morristown